Protocolnummer: volgt

PrimerX

Deze studie wordt voorbereid, en heeft op basis van het design het endorsed label gekregen.

A prospective study of primary metastatic renal cell carcinoma treated with immunecheckpoint inhibitors and the primary tumour in place (PRIMER)

Doel van het onderzoek


OBJECTIVES 2.1 Aims

  1. To assess the benefit of deferred CN in mRCC patients undergoing IO combination treatment.
  2. To investigate efficacy of first line IO combination therapies on the primary tumor.
  3. To collect clinical data and sequenial tissue from patients with primary metastatic renal cell carcinoma who receive IO combinations as standard of care, for translational research into mechanisms of response and resistance to treatment.

Contactpersoon

PRO-RCC
 

A. Bex, Antoni van Leeuwenhoek, Amsterdam
A. Bins, AmsterdamUMC

Bekijk alle trials